CEO of UnitedHealthcare, Brian Thompson, shot dead in New York City
The CEO of US healthcare insurance firm UnitedHealthcare Group has been shot dead by a masked gunman outside of the …
The CEO of US healthcare insurance firm UnitedHealthcare Group has been shot dead by a masked gunman outside of the …
Eli Lilly has scored a win in the ongoing competition with Novo Nordisk in the obesity space, as a Phase …
The judicious use of real-world data (RWD) could keep a Phase I or II trial from collapsing with the market …
Mexico's alcohol consumption patterns and their population-level health effects have received little scholarly attention, despite alcohol consumption’s status as a …
Vaxcyte has commenced the Phase II trial of its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31, in healthy infants, with …
Trial sites and sponsors have been urged to consider the burden of arbitrary data collection on patients participating in trials …
Airline passenger numbers may have been slow to rise after the Covid-19 pandemic, but air cargo’s rebound was much quicker. …
Cartesian Therapeutics has announced updated efficacy and safety data from the Phase IIb trial of its mRNA cell therapy candidate …
China-headquartered VivaVision Biotech is looking to advance its non-steroidal therapy, VVN461-CS-201 (VVN461), in a Phase III trial after the candidate …
Arrowhead Pharmaceuticals has submitted an application to the New Zealand Medicines and Medical Devices Safety Authority seeking clearance to commence …
Assumptions, poor record keeping, or a lack of viable information can stand in the way of trial progress and push …
Gate Neurosciences and the University of Pittsburgh (Pitt) have commenced a Phase II clinical trial to evaluate the potential of …
Pneumonia epidemic peaks historically occur every four to seven years, with the last epidemic of pneumonia in the UK occurring …
Southeast Asia offers a unique opportunity for sponsors conducting clinical trials with vaccine candidates including faster recruitment, lower costs, and …
US-based biotechnology company Spyre Therapeutics has begun dosing healthy volunteers in Phase I studies of two investigational monoclonal antibodies. The drug …